
Most patients who were switched from adalimumab (Humira, AbbVie) to an interchangeable biosimilar experienced clinical success, with the vast majority remaining on a biosimilar three months after conversion, according to a study conducted at Brown University Health and presented in a poster (38-M) at the ASHP Pharmacy Futures 2025 meeting.
The study used data from the center’s electronic health records and specialty pharmacy from Jan. 1, 2023, to June 1, 2024. The primary